# Leadsynbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leadsynbio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.leadsynbio.com
- Latest round: Series D (Aug 11, 2023)
- Investors on record: 8

## About

Based in Jiangsu, China and founded in 2015, Suzhou Leadsynbio Technology Co., Ltd., dba Leadsynbio, is a biotechnology specialized in producing and providing biopharmaceutical ingredients and nutritional materials using proprietary synthetic biology technologies. The company has established production facilities in provinces of Hunan and Anhui, China, as well as R&D centers in Jiangsu, China and the United States.

In September 2026, Leadsynbio raised CNY 450 million in Pre-IPO funding from Oriza Holdings, Changde Yuanli Industry Investment Holdings, Hunan Chasing Fund Management, Suzhou Capital Group, Suzhou Industrial Investment Private Equity Fund Management, Harvest Capital, Beijing Chuang Fund Investment Management, and other investors.

Leadsynbio mainly provides APIs (Active Pharmaceutical Ingredients), pharmaceutical intermediates, human nutritional ingredients (such as beta-NMN (ß-nicotinamide mononucleotide) and NAD (Nicotinamide Adenine Dinucleotide)), and animal nutritional ingredients (such as 25-Hydroxyvitamin D3) needed for pharmaceuticals, nutraceuticals and animal health products. 

The company generates revenue through the sale of biopharmaceutical ingredients and other related products.

The company will primarily use the Pre-IPO funding in late September 2026 for the R&D and industrialization of new products, the expansion of market reach, and the comprehensive enhancement of its overall competitiveness.

## Funding rounds

- Series D, Aug 11, 2023 — Lilly Asia Ventures, Sherpa Healthcare Partners
- Series C, Feb 8, 2022 — Lilly Asia Ventures
- Series C, Dec 16, 2021 — GF Qianhe, Sherpa Healthcare Partners, Hunan Chasing Fund Management, GL Ventures, New Hope Group
- Series B, Aug 27, 2019 — Lianjing Capital, Chobe Capital
- Series A, Nov 1, 2017 — Chobe Capital

## Investors

- Chobe Capital (https://capitalatlas.ai/funds/chobe-capital) — Series A, Series B
- Lianjing Capital (https://capitalatlas.ai/funds/lianjing-capital) — Series B
- GF Qianhe — Series C
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series C, Series D
- Hunan Chasing Fund Management (https://capitalatlas.ai/funds/hunan-chasing-fund-management) — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- New Hope Group (https://capitalatlas.ai/funds/new-hope-group) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C, Series D